Story thread · 3 reports / 3 sources
Argenx Soars on Latest Trial Success for Autoimmune Drug Vyvgart
bloomberg.com · 3h · first report
Argenx SE’s shares jumped after the European biotech reported the latest large, successful trial for its blockbuster drug Vyvgart.
The coverage
- Argenx declares Phase 3 win for Vyvgart Hytrulo in autoimmune myositis
endpts.com · 50m
- Argenx advances as Vyvgart hits key trial endpoints for autoimmune myositis
seekingalpha.com · 3h
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.